Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
all decrease » small decrease (Expand Search), a decrease (Expand Search), awd decreased (Expand Search)
Showing 2,861 - 2,880 results of 21,342 for search '(( significant ((all decrease) OR (fold decrease)) ) OR ( significant decrease decrease ))', query time: 0.39s Refine Results
  1. 2861
    Acceptance of the HPV vaccine.

    Acceptance of the HPV vaccine. by Mohammad Delwer Hossain Hawlader (11558838)

    Published 2024
    Subjects: “…considered statistically significant…”
    Save to List
    Saved in:
  2. 2862
    Cues to the action question.

    Cues to the action question. by Mohammad Delwer Hossain Hawlader (11558838)

    Published 2024
    Subjects: “…considered statistically significant…”
    Save to List
    Saved in:
  3. 2863
    Characteristics of the respondents (n = 2,151).

    Characteristics of the respondents (n = 2,151). by Mohammad Delwer Hossain Hawlader (11558838)

    Published 2024
    Subjects: “…considered statistically significant…”
    Save to List
    Saved in:
  4. 2864
    Determinants of HPV vaccine acceptance.

    Determinants of HPV vaccine acceptance. by Mohammad Delwer Hossain Hawlader (11558838)

    Published 2024
    Subjects: “…considered statistically significant…”
    Save to List
    Saved in:
  5. 2865
    Quantification of single cell areas during MgOx treatment.

    Quantification of single cell areas during MgOx treatment. by Justin Greene (306625)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 2866
    ROC Results Predicted in the Sample.

    ROC Results Predicted in the Sample. by Fangyi Yang (18867853)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 2867
    ROC Results Predicted for Out of the Sample.

    ROC Results Predicted for Out of the Sample. by Fangyi Yang (18867853)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 2868
    Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff

    Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
    Save to List
    Saved in:
  9. 2869
    Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx

    Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
    Save to List
    Saved in:
  10. 2870
    Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff

    Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
    Save to List
    Saved in:
  11. 2871
    Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc

    Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
    Save to List
    Saved in:
  12. 2872
    Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff

    Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”
    Save to List
    Saved in:
  13. 2873
    Effect of different doses of the defatted extract (DE) of the leaves of <i>S. malaccense</i> and <i>S. samarangense</i> on urea and creatinine levels. Data represented as mean±SEM of n = 7, a: significant from the control group at <i>p</i> < 0.001, b: significant from the CdCl<sub>2</sub> group at <i>p</i> < 0.001.

    Effect of different doses of the defatted extract (DE) of the leaves of <i>S. malaccense</i> and <i>S. samarangense</i> on urea and creatinine levels. Data represented as mean±SEM... by Fatma A. Moharram (9276104)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 2874
    The results of linear mixed model.

    The results of linear mixed model. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 2875
    The flow of the participants from enrollment to analysis.

    The flow of the participants from enrollment to analysis. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 2876
    Correlation between treatment-induced changes in lumbar motor control and N150 amplitude.

    Correlation between treatment-induced changes in lumbar motor control and N150 amplitude. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 2877
    Sensory-evoked potentials of N80 and N150.

    Sensory-evoked potentials of N80 and N150. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 2878
    The mean and standard deviation of outcome measures.

    The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 2879
    Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data.

    Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 2880
    The demographical and clinical characteristics of subjects at baseline.

    The demographical and clinical characteristics of subjects at baseline. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: